These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 1968912)
1. Beta-adrenoceptor blockade and CNS-related subjective symptoms: a randomized, double-blind, placebo-controlled comparison of metoprolol CR/ZOK, atenolol and propranolol LA in healthy subjects. Dimenäs E; Kerr D; Macdonald I J Clin Pharmacol; 1990 Feb; 30(S2):S103-7. PubMed ID: 1968912 [TBL] [Abstract][Full Text] [Related]
2. Comparison of CNS-related subjective symptoms in hypertensive patients treated with either a new controlled release (CR/ZOK) formulation of metoprolol or atenolol. Dimenäs E; Ostergren J; Lindvall K; Dahlöf C; Westergren G; de Faire U J Clin Pharmacol; 1990 Feb; 30(S2):S82-90. PubMed ID: 2179286 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic properties of controlled release (CR/ZOK) metoprolol in healthy Oriental subjects: a comparison with conventional formulations of metoprolol and atenolol. Darmansjah I; Wong E; Setiawati A; Moeloek D; Irawati D; Siagian M; Muchtar A J Clin Pharmacol; 1990 Feb; 30(S2):S39-45. PubMed ID: 2312778 [TBL] [Abstract][Full Text] [Related]
4. Beta-adrenoceptor blockade and hypoglycaemia. A randomised, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects. Kerr D; MacDonald IA; Heller SR; Tattersall RB Br J Clin Pharmacol; 1990 Jun; 29(6):685-93. PubMed ID: 1974143 [TBL] [Abstract][Full Text] [Related]
5. CNS-related subjective symptoms during treatment with beta 1-adrenoceptor antagonists (atenolol, metoprolol): two double-blind placebo controlled studies. Dimenäs E; Dahlöf C; Olofsson B; Wiklund I Br J Clin Pharmacol; 1989 Nov; 28(5):527-34. PubMed ID: 2574052 [TBL] [Abstract][Full Text] [Related]
6. Effects of 100 mg of controlled-release metoprolol and 100 mg of atenolol on blood pressure, central nervous system-related symptoms, and general well being. Walle PO; Westergren G; Dimenäs E; Olofsson B; Albrektsen T J Clin Pharmacol; 1994 Jul; 34(7):742-7. PubMed ID: 7929868 [TBL] [Abstract][Full Text] [Related]
7. Effects of a week's beta-adrenoceptor blockade with atenolol and metoprolol CR/ZOK on the response to exercise in healthy women aged 50 to 70 years. Patrick J; Bassey J; Morrant J; Macdonald I J Clin Pharmacol; 1990 Feb; 30(S2):S108-16. PubMed ID: 2312773 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. Lücker P; Moore G; Wieselgren I; Olofsson B; Bergstrand R J Clin Pharmacol; 1990 Feb; 30(S2):S17-27. PubMed ID: 2312775 [TBL] [Abstract][Full Text] [Related]
9. Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects--a comparison with atenolol. Dimenäs ES; Dahlöf CG; Heibel B; Moore RG; Olofsson BK; Westergren GE; Lücker PW Eur J Clin Pharmacol; 1990; 38(6):571-8. PubMed ID: 2373131 [TBL] [Abstract][Full Text] [Related]
10. A double-blind comparison of once-daily metoprolol controlled-release and atenolol in the treatment of Chinese patients with mild to moderate hypertension. Chen MF; Yang CY; Chen WJ; Lee CM; Wu CC; Liau CS; Lee YT Cardiovasc Drugs Ther; 1995 Jun; 9(3):401-6. PubMed ID: 8527349 [TBL] [Abstract][Full Text] [Related]
11. Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease. Plosker GL; Clissold SP Drugs; 1992 Mar; 43(3):382-414. PubMed ID: 1374320 [TBL] [Abstract][Full Text] [Related]
12. A double-blind comparison of metoprolol CR/ZOK 50 mg and atenolol 50 mg once daily for uncomplicated hypertension. Klein G; Berger J; Olsson G; Menzel T J Clin Pharmacol; 1990 Feb; 30(S2):S72-7. PubMed ID: 2179284 [TBL] [Abstract][Full Text] [Related]
13. Is metoprolol CR/ZOK more selective than conventional metoprolol and atenolol? Kendall M; Akhlaghi S; Hughes B; Lewis H J Clin Pharmacol; 1990 Feb; 30(S2):S98-102. PubMed ID: 2155948 [TBL] [Abstract][Full Text] [Related]
14. Treatment with beta-blockers--the value of an even plasma concentration over 24 h. Agewall S; Kendall M J Clin Pharm Ther; 1997 Jun; 22(3):171-9. PubMed ID: 9447471 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: a comparison with atenolol. Blomqvist I; Westergren G; Sandberg A; Jonsson UE; Lundborg P Eur J Clin Pharmacol; 1988; 33 Suppl():S19-24. PubMed ID: 3371390 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR/ZOK) 50 mg in young subjects. Wieselgren I; Lundborg P; Sandberg A; Olofsson B; Bergstrand R J Clin Pharmacol; 1990 Feb; 30(S2):S28-32. PubMed ID: 2312776 [TBL] [Abstract][Full Text] [Related]
17. The effects of combined treatment with beta 1-selective receptor antagonists and lipid-lowering drugs on fat metabolism and measures of fatigue during moderate intensity exercise: a placebo-controlled study in healthy subjects. Eagles CJ; Kendall MJ Br J Clin Pharmacol; 1997 Mar; 43(3):291-300. PubMed ID: 9088584 [TBL] [Abstract][Full Text] [Related]
18. Exercise metabolism in healthy volunteers taking atenolol, high and low doses of metoprolol CR/Z0K, and placebo. Head A; Maxwell S; Kendall MJ; Eagles C Br J Clin Pharmacol; 1994 Dec; 38(6):499-504. PubMed ID: 7888287 [TBL] [Abstract][Full Text] [Related]
19. A pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK with a conventional slow release preparation. Oosterhuis B; Jonkman J; Zuiderwijk P; Sollie F J Clin Pharmacol; 1990 Feb; 30(S2):S33-8. PubMed ID: 2312777 [TBL] [Abstract][Full Text] [Related]
20. Pulmonary effects of long-term beta 2-blockade in healthy subjects: comparative study of metoprolol OROS. Bauer K; Rakusan S; Kaik G Am Heart J; 1990 Aug; 120(2):473-7. PubMed ID: 1974382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]